Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional
Official Title: A Phase I/II Trial of PTC299 in Patients With HIV-Related Kaposi's Sarcoma
Brief Summary:
RATIONALE: PTC299 may stop the growth of Kaposi sarcoma by blocking blood flow to the tumor.
PURPOSE: This phase I/II trial is studying the side effects and best dose of PTC299 and to see how well it works in treating patients with HIV-related Kaposi sarcoma.